Special receptacle or package – For ampule – capsule – pellet – or granule – Single layer in edge-to-edge array
Patent
1997-10-09
2000-07-25
Sewell, Paul T.
Special receptacle or package
For ampule, capsule, pellet, or granule
Single layer in edge-to-edge array
2064595, 514343, B65D 8304, A61K 3144
Patent
active
060926600
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention find is applicable within the field of using placebo for judging whether an observed improvement in a patient's symptoms results from pharmacological treatment or a placebo effect, or is a spontaneous event. More specifically, the present invention relates to a blister pack arrangement for implementing a Single Subject Trial of a type referred to as a Random Starting Day Trial.
BACKGROUND OF THE INVENTION
For many conditions, such as dyspepsia, asthma, headache and arthritis, it is often difficult to judge whether an observed improvement in a patient's symptoms results from pharmacological treatment or a placebo effect, or is a spontaneous event. To overcome this problem; Single Subject Trials (N-of-1 trials) were designed. These have a long tradition of use in psychology and psychiatry, but the early studies were often non-randomised and the evaluation of the observations was largely subjective. In the 1980s, single subject trials were re-introduced to assist in decisions on a drug's efficacy in the treatment of an individual patient. The design of the trial was refined, and in the revised design the patient is given an active drug and placebo in randomised order in a double-blind cross-over manner for a series of consecutive periods (of up to 1 week). The judgement of the drug's efficacy is based on a comparison of symptoms during active treatment periods with those during placebo periods.
There are, however, some statistical problems and weakness associated with this design of trial. Inferential problems of the multiple cross-over design emanate from two sources: observations from adjacent periods are likely to be auto-correlated (i.e. more similar than observations that are more distant in time) and carry-over effects from the preceding period are not uncommon. Thus the basic and fundamental assumption of independence between observations that underlies most statistical methods is likely to be more or less violated, and there is an increased risk of significance tests and confidence intervals resulting in false conclusions.
Furthermore, a Single Subject Trial with multiple cross-over design is not suitable for testing the efficacy of drugs with a long duration of action (i.e. several days), because it necessitates the inclusion of wash-out periods, which prolongs the trial. The trial length may be critical for conditions with spontaneous variations in disease activity.
In an attempt to overcome these problems, a novel alternative, The Random Starting Day (RSD) trial, has been designed and briefly described in an abstract presented at the World Congress of Gastroenterology, Oct. 2-7,1994. According to said abstract the basic principle of the RSD trial is as follows: The patient starts on placebo and, on a randomly chosen day, switches to the active drug for the remainder of the trial period. The day for switching is randomly determined and varies between patients, and it is known neither to the patient nor the investigator or physician.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide means for implementing an RSD Trial.
It is another object to provide means for implementing an RSD Trial for a group of patients.
It is yet another object to provide means for implementing an RSD Trial in an easy and cost-effective, but still reliable way.
It is still another object to provide such means for implementing an RSD Trial which the patient can start to use directly after delivery over-the-counter, without any need of action by a physician until the end of a trial period.
In view of these objects the invention provides a blister pack arrangement which comprises: at least one blister pack with individually openable blisters including a number of blisters containing placebo, referred to as placebo blisters, and a number of blisters containing an active pharmaceutical drug, referred to as drug blisters; indicia means providing user information that indicates a predetermined sequence in which said blisters are to be opened during a trial period
REFERENCES:
patent: 4616316 (1986-10-01), Hanpeter et al.
patent: 5072430 (1991-12-01), Eckernas et al.
patent: 5597072 (1997-01-01), Lieberman et al.
patent: 5747512 (1998-05-01), Keenan et al.
patent: 5803499 (1998-09-01), Tung et al.
patent: 5869505 (1999-02-01), Keenan
Eriksson Sven
Rune Simon
Astra Aktiebolag
Bui Luan K.
Sewell Paul T.
LandOfFree
Blister pack arrangement does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Blister pack arrangement, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Blister pack arrangement will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1330526